*Today's Featured Stock: The Future of Air Travel Is Unfolding—Unlock the name and symbol right here.
It’s time to buy down, but not out obesity stocks, we said just weeks ago.
With more drug trial data expected, related stocks could rocket even higher – especially with obesity rates still bursting at the seams. At the moment, according to the U.S. Centers for Disease Control and Prevention, “Blockbuster growth in weight-loss drugs was the main driver of a 13.5% increase in spending on prescription medications in the U.S. in 2023, according to ASHP's (American Society of Health-System Pharmacists) report,” as noted by the American Society of Health-System Pharmacists. Company:
Viking Therapeutics “VK2735 could set itself apart from existing weight loss drugs as it is a GLP1/GIP agonist being developed for an induction (injection [SQ] weekly) and maintenance (oral [PO] or SQ monthly) paradigm.”
Edge on the Street
A $12 billion powerhouse doesn't waste resources on just any project.
Get the full details here!
|
Altimmune (SYM: ALT) With what we estimate as a large potential opportunity for pemvidutide in obesity and MASH combined and ALT at a roughly $508M cap, we think ALT is undervalued.” |
The Oxford Club
This industry set to BOOM in Trump’s first year
Morgan Stanley just initiated coverage of Structure Therapeutics with an overweight rating, believing there is room in the diabetes and obesity drug market for oral GLP-1 drugs.
The firm added that early data suggests Structure’s oral drug candidate GSBR-1290, an GLP-1R agonist, has a competitive profile. It sees a potential U.S. launch in 2028, with the drug reaching worldwide sales of $6.3 billion in 2040. Morgan Stanley says it expects Phase 2b data for the drug in obesity, anticipated by the end of 2025, to be the next catalyst for the program.